The novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase

Neurobiology of Aging

Volumn 35, Issue 6, 2014, Pages 1255-1274

  Park, Hyun Hee ^a   Lee, Kyu Yong ^a   Kim, Sangjae ^b   Lee, Jessica Woojin ^b   Choi, Na Young ^c   Lee, Eun Hye ^c   Lee, Young Joo ^a   Lee, Sang Hun ^a   Koh, Seong Ho ^a,c  

^a Hanyang University College of Medicine   (South Korea)

^b Department of Neuroscience   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

GV1001; Neural stem cells; Oligomer; Peptide; Vaccine; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; BETA CATENIN; CYCLIN D1; FREE RADICAL; HIGH MOBILITY GROUP B1 PROTEIN; MYC PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TERTOMOTIDE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (25-35); ANTIOXIDANT; MITOCHONDRIAL PROTEIN; NEUROPROSTANE; PEPTIDE FRAGMENT; TELOMERASE;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN MITOCHONDRION; CELL LEVEL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG EFFECT; EMBRYO; FETUS; HUMAN; HUMAN CELL; NERVE CELL CULTURE; NERVE CELL LESION; NEURAL STEM CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEM CELL MOBILIZATION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL MOTION; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; TOXICITY;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MITOCHONDRIAL PROTEINS; NEURAL STEM CELLS; NEUROPROSTANES; PEPTIDE FRAGMENTS; RATS; TELOMERASE;

EID: 84903367193     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.12.015     Document Type: Article

References (45)

1. Bernhardt S.L., Gjertsen M.K., Trachsel S., Moller M., Eriksen J.A., Meo M., Buanes T., Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br. J. Cancer 2006, 95:1474-1482. 10.1038/sj.bjc.6603437.
2. Broersen K., Rousseau F., Schymkowitz J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?. Alzheimer's Res. Ther. 2010, 2:12. 10.1186/alzrt36.
3. Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., Dyrhaug M., Trachsel S., Moller M., Eriksen J.A., Gaudernack G. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. CII 2006, 55:1553-1564. 10.1007/s00262-006-0145-7.
4. Brunsvig P.F., Kyte J.A., Kersten C., Sundstrom S., Moller M., Nyakas M., Hansen G.L., Gaudernack G., Aamdal S. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin. Cancer Res. Official J. Am. Assoc. Cancer Res. 2011, 17:6847-6857. 10.1158/1078-0432.CCR-11-1385.
5. Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26:267-298. 10.1146/annurev.neuro.26.010302.081142.
6. Chase L.G., Lakshmipathy U., Solchaga L.A., Rao M.S., Vemuri M.C. Anovel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res. Ther. 2010, 1:8. 10.1186/scrt8.
7. Chiodi I., Mondello C. Telomere-independent functions of telomerase in nuclei, cytoplasm, and mitochondria. Front. Oncol. 2012, 2:133. 10.3389/fonc.2012.00133.
8. Chojnacki A., Weiss S. Production of neurons, astrocytes and oligodendrocytes from mammalian CNS stem cells. Nat. Protoc. 2008, 3:935-940. 10.1038/nprot.2008.55.
9. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9:387-398. 10.1038/nrd2896.
10. Coulson E.J. Does the p75 neurotrophin receptor mediate abeta-induced toxicity in Alzheimer's disease?. J.Neurochem. 2006, 98:654-660. 10.1111/j.1471-4159.2006.03905.x.
11. Currle D.S., Hu J.S., Kolski-Andreaco A., Monuki E.S. Culture of mouse neural stem cell precursors. J.Vis. Exp. 2007, 152. 10.3791/152.
12. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J.Biol. Chem. 2002, 277:32046-32053. 10.1074/jbc.M201750200.
13. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J.Biol. Chem. 2007, 282:11590-11601. 10.1074/jbc.M607483200.
14. Fernandez J., Gharahdaghi F., Mische S.M. Routine identification of proteins from sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels or polyvinyl difluoride membranes using matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS). Electrophoresis 1998, 19:1036-1045. 10.1002/elps.1150190619.
15. Greten T.F., Forner A., Korangy F., N'Kontchou G., Barget N., Ayuso C., Ormandy L.A., Manns M.P., Beaugrand M., Bruix J. Aphase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC cancer 2010, 10:209. 10.1186/1471-2407-10-209.
16. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 2007, 8:101-112. 10.1038/nrm2101.
17. Hunger R.E., Kernland Lang K., Markowski C.J., Trachsel S., Moller M., Eriksen J.A., Rasmussen A.M., Braathen L.R., Gaudernack G. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol. Immunother. CII 2011, 60:1553-1564. 10.1007/s00262-011-1061-z.
18. Inderberg-Suso E.M., Trachsel S., Lislerud K., Rasmussen A.M., Gaudernack G. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 2012, 1:670-686. 10.4161/onci.20426.
19. Jiang Q., Gu Z., Zhang G., Jing G. Diphosphorylation and involvement of extracellular signal-regulated kinases (ERK1/2) in glutamate-induced apoptotic-like death in cultured rat cortical neurons. Brain Res. 2000, 857:71-77.
20. Jimenez S., Torres M., Vizuete M., Sanchez-Varo R., Sanchez-Mejias E., Trujillo-Estrada L., Carmona-Cuenca I., Caballero C., Ruano D., Gutierrez A., Vitorica J. Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J.Biol. Chem. 2011, 286:18414-18425. 10.1074/jbc.M110.209718.
21. Koh S.H., Noh M.Y., Cho G.W., Kim K.S., Kim S.H. Erythropoietin increases the motility of human bone marrow-multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells Dev. 2009, 18:411-421. 10.1089/scd.2008.0040.
22. Kokhaei P., Palma M., Hansson L., Osterborg A., Mellstedt H., Choudhury A. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp. Hematol. 2007, 35:297-304. 10.1016/j.exphem.2006.10.006.
23. Kyte J.A. Cancer vaccination with telomerase peptide GV1001. Expert. Opin. Investig. Drugs 2009, 18:687-694. 10.1517/13543780902897631.
24. Kyte J.A., Gaudernack G., Dueland S., Trachsel S., Julsrud L., Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin. Cancer Res. Official J. Am. Assoc. Cancer Res. 2011, 17:4568-4580. 10.1158/1078-0432.CCR-11-0184.
25. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509. 10.1038/nrn2168.
26. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A 1998, 95:6448-6453.
27. Lange S.S., Mitchell D.L., Vasquez K.M. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc. Natl. Acad. Sci. U.S.A 2008, 105:10320-10325. 10.1073/pnas.0803181105.
28. Lee Y.J., Park K.H., Park H.H., Kim Y.J., Lee K.Y., Kim S.H., Koh S.H. Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway. J.Neurochem. 2009, 111:90-100.
29. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. Aspecific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357. 10.1038/nature04533.
30. Magdesian M.H., Carvalho M.M., Mendes F.A., Saraiva L.M., Juliano M.A., Juliano L., Garcia-Abreu J., Ferreira S.T. Amyloid-beta binds to the extracellular cysteine-rich domain of frizzled and inhibits Wnt/beta-catenin signaling. J.Biol. Chem. 2008, 283:9359-9368. 10.1074/jbc.M707108200.
31. Martinez P., Blasco M.A. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat. Rev. Cancer 2011, 11:161-176. 10.1038/nrc3025.
32. Middleton G., Ghaneh P., Costello E., Greenhalf W., Neoptolemos J.P. New treatment options for advanced pancreatic cancer. Expert. Rev. Gastroenterol. Hepatol. 2008, 2:673-696. 10.1586/17474124.2.5.673.
33. Nakagami Y. Inhibitors beta-amyloid-induced toxicity by modulating the Akt signaling pathway. Drug News Perspect. 2004, 17:655-660.
34. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., Morgan T.E., Rozovsky I., Stine W.B., Snyder S.W., Holzman T.F., Krafft G.A., Finch C.E. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 1995, 136:22-31.
35. Park H.H., Lee K.Y., Kim S.H., Lee Y.J., Koh S.H. L-DOPA-induced neurotoxicity is reduced by the activation of the PI3K signaling pathway. Toxicology 2009, 265:80-86. 10.1016/j.tox.2009.09.011.
36. Sakono M., Zako T. Amyloid oligomers: formation and toxicity of abeta oligomers. FEBS J. 2010, 277:1348-1358. 10.1111/j.1742-4658.2010.07568.x.
37. Salomone S., Caraci F., Leggio G.M., Fedotova J., Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol. 2012, 73:504-517. 10.1111/j.1365-2125.2011.04134.x.
38. Schlapbach C., Yerly D., Daubner B., Yawalkar N., Hunger R.E. Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma. J.Dermatol. Sci. 2011, 62:75-83. 10.1016/j.jdermsci.2011.02.001.
39. Shaw V.E., Naisbitt D.J., Costello E., Greenhalf W., Park B.K., Neoptolemos J.P., Middleton G.W. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert. Rev. Vaccines 2010, 9:1007-1016. 10.1586/erv.10.92.
40. Smith L., Watson M.B., O'Kane S.L., Drew P.J., Lind M.J., Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer Ther. 2006, 5:2115-2120. 10.1158/1535-7163.MCT-06-0190.
41. Stewart S.A., Weinberg R.A. Telomeres: cancer to human aging. Annu. Rev. CellDev. Biol. 2006, 22:531-557. 10.1146/annurev.cellbio.22.010305.104518.
42. Studer L., Tabar V., McKay R.D. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat. Neurosci. 1998, 1:290-295. 10.1038/1105.
43. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
44. Yamamoto N., Matsubara E., Maeda S., Minagawa H., Takashima A., Maruyama W., Michikawa M., Yanagisawa K. Aganglioside-induced toxic soluble abeta assembly. Its enhanced formation from abeta bearing the arctic mutation. J.Biol. Chem. 2007, 282:2646-2655. 10.1074/jbc.M606202200.
45. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008, 22:246-260. 10.1096/fj.06-7703com.